Remission of chronic inflammatory demyelinating polyneuropathy after hepatitis C virus eradication with sofosbuvir and ledipasvir therapy.

Tsuzaki, Koji; Someda, Hitoshi; Inoue, Manabu; Tachibana, Naoko; Hamano, Toshiaki

Tsuzaki, Koji; Someda, Hitoshi; Inoue, Manabu; Tachibana, Naoko; Hamano, Toshiaki.

Affiliation

Tsuzaki K; Department of Neurology, Kansai Electric Power Hospital, Osaka, Japan.
Someda H; Department of Gastroenterology and Hepatology, Kansai Electric Power Hospital, Osaka, Japan.
Inoue M; Department of Neurology, Osaka City General Hospital, Osaka, Japan.
Tachibana N; Department of Neurology, Kansai Electric Power Hospital, Osaka, Japan.
Hamano T; Department of Neurology, Kansai Electric Power Hospital, Osaka, Japan.

Muscle Nerve ; 58(5): E34-E36, 2018 11.

Article in En | MEDLINE | ID: mdl-30028899

Subject(s)

Antiviral Agents/adverse effects; Benzimidazoles/adverse effects; Fluorenes/adverse effects; Hepatitis C/drug therapy; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating/chemically induced; Sofosbuvir/adverse effects; Hepacivirus/pathogenicity; Hepatitis C/complications; Humans; Immunoglobulins, Intravenous/therapeutic use; Immunologic Factors/therapeutic use; Male; Middle Aged; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating/complications; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating/drug therapy; Recurrence

Key words

CIDP; HCV; ledipasvir; sofosbuvir; sustained virological response

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Benzimidazoles / Hepatitis C / Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Fluorenes / Sofosbuvir Limits: Humans / Male / Middle aged Language: En Journal: Muscle Nerve Year: 2018 Document type: Article Affiliation country: Japan

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google